Some characteristics such as tumor mutational burden, deficiency of mismatch repair, host expression of PD-1/PD-L1 and the density of tumor-infiltrating lymphocytes have been reported as promising biomarkers for anti-PD-1 therapy [8]. This evidence concerns the gene CD274 and neoplasm.